Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction

Background—The early response of C-reactive protein to initiation of a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) is not known. The purpose of this study was to determine the rate at which highly sensitive C-reactive protein (hsCRP) levels change after initiation of simvastatin and whether this occurs independently of the change in LDL cholesterol. Methods and Results—The study was a crossover, double-blind design including 40 subjects with elevated LDL cholesterol. Subjects were randomly assigned to 1 of 2 groups: simvastatin 40 mg for 14 days, then placebo for 14 days, or placebo first, then simvastatin. Simvastatin decreased LDL cholesterol by 56±4 mg/dL (P <0.0001) at day 7 and by an additional 8±3 mg/dL (P =0.02) at day 14. Baseline log(hsCRP) levels were similar in the 2 groups. By day 14, log(hsCRP) was significantly lower in patients on simvastatin when compared with placebo (P =0.011). Although there was no significant difference in fibrinogen levels, simvastatin produced a modest increase in log[lipoprotein(a)] (P =0.03) at days 7 and 14. There were no relationships between the decrease in LDL cholesterol and the decrease in hsCRP. Conclusions—Simvastatin lowers hsCRP by 14 days, independent of its effect on LDL cholesterol. This rapid impact of a statin on hsCRP has potential implications in the management of acute coronary syndromes.

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  T. Sampietro,et al.  Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin , 1995, Cardiovascular Drugs and Therapy.

[3]  H. White,et al.  Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes , 2002, Circulation.

[4]  Deepak L. Bhatt,et al.  Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.

[5]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[6]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[7]  R. Munford.  Statins and the acute-phase response. , 2001, The New England journal of medicine.

[8]  P. Ridker,et al.  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.

[9]  A. Szczeklik,et al.  Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. , 2001, International journal of cardiology.

[10]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[11]  N. Rifai,et al.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). , 2000, Clinical chemistry.

[12]  D. Papanicolaou,et al.  Chronic systemic inflammation in overweight and obese adults. , 2000, JAMA.

[13]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[14]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[15]  A. Folsom.  "New" risk factors for atherosclerotic diseases. , 1999, Experimental gerontology.

[16]  P. Meraj,et al.  Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. , 1999, Journal of the American College of Cardiology.

[17]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[18]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[19]  M. Pfeffer,et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.

[20]  S. Coppack,et al.  Adipose tissue as an endocrine and paracrine organ , 1998, International Journal of Obesity.

[21]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[22]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[23]  R J Glynn,et al.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.

[24]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[25]  J. Kjekshus,et al.  Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study , 1997, Clinical genetics.

[26]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[27]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[28]  E. Wijsman,et al.  Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. , 1996, Journal of lipid research.

[29]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[30]  S. Haffner,et al.  Effect of simvastatin on Lp(a) concentrations , 1995, Clinical cardiology.

[31]  J. Ramires,et al.  Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. , 1995, International journal of cardiology.

[32]  M. Koschinsky,et al.  Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). , 1995, Clinical chemistry.

[33]  I. Otterness.  The value of C-reactive protein measurement in rheumatoid arthritis. , 1994, Seminars in arthritis and rheumatism.

[34]  J. Ordovás,et al.  Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. , 1994, JAMA.

[35]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.